Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 71.6%

Neg 71.6% Neu 0% Pos 0%

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $43 to $40.